Clinical trials: Allergic Conjunctivitis
Rhinitis Allergic, Conjunctivitis
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
This is a study to evaluate the efficacy and safety of grass sublingual tablet (SCH 697243) versus placebo in the treatment of grass pollen-induced allergic hayfever symptoms.
- Trial name
- NCT01385371
- Testing
- Grass (Phleum pratense) pollen allergen extract
- Volunteers
- 1,501 people
- Sponsor
- ALK-Abelló A/S
Seasonal Allergic Conjunctivitis to Ragweed
A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.
The purpose of this study is to test if olopatadine punctal plugs can reduce the symptoms (itching) of allergic conjunctivitis to ragweed in an Environmental Exposure Chamber model.
- Trial name
- NCT01287338
- Testing
- Olopatadine
- Where
- Canada
- Volunteers
- 143 people
- Sponsor
- Mati Therapeutics Inc.
Allergic Conjunctivitis
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday® Once Daily Relief Extra Strength and Claritin® Tablets 24-Hour will be made using the Ora-CAC…
- Trial name
- NCT05265910
- Testing
- olopatadine hydrochloride ophthalmic solution 0.7%, loratadine 10 mg, Tears Naturale
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Andover Research Eye Institute
Chronic Allergic Conjunctivitis
OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of…
- Trial name
- NCT02062905
- Testing
- Dexamethasone
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Ocular Therapeutix, Inc.
Allergic Conjunctivitis
An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis
The objective of this study is to assess safety and efficacy of long-term use of AL-4943A (Olopatadine Hydrochloride Ophthalmic Solution, 0.2%) in patients with allergic conjunctivitis.
- Trial name
- NCT01037179
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
- Where
- Japan
- Volunteers
- 110 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis
The purpose of this study is to evaluate the efficacy and safety of an anti-allergy drug with a contact lens compared to placebo in preventing ocular itching associated with allergic conjunctivitis
- Trial name
- NCT00445874
- Testing
- Ketotifen with a Contact Lens (no generic name)
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Vistakon Pharmaceuticals
Allergic Conjunctivitis
A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- NCT01551056
- Testing
- AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Aciex Therapeutics, Inc.
Allergic Conjunctivitis
Patient Perception Study for AL-4943A
To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis previously treated with a topical ocular anti-allergy leukotriene-release inhibitor medication.
- Trial name
- NCT01294969
- Testing
- AL-4943A
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Alcon Research
Persistent Corneal Epithelial Defect
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants…
- Trial name
- NCT07519902
- Testing
- Cenegermin, Vehicle
- Where
- 77 sites in United States, Argentina and 12 more
- Volunteers
- 150 people
- Sponsor
- Dompé Farmaceutici S.p.A
Allergic Conjunctivitis
An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis
The purpose of this study is to evaluate the onset and duration of action of two concentrations of AKF-1 Ophthalmic Solution compared to vehicle in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis.
- Trial name
- NCT01561521
- Testing
- AKF-1
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Akorn, Inc.
Allergic Conjunctivitis
A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults
The main goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles* of MDI-1228_mesylate Ophthalmic Solution in healthy adult participants.
- Trial name
- NCT05969236
- Testing
- MDI-1228_mesylate Ophthalmic Solution
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shanghai Medinno Pharmaceutical Technology Co., Ltd.
Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic
Twin SUBLIVAC® Grasses Clinical Efficacy Study
To show that treatment with SUBLIVAC® Grasses is clinically effective by means of reduction in allergic symptoms and/or use of allergic symptomatic medication in subjects suffering from IgE mediated allergic complaints triggered…
- Trial name
- NCT00422149
- Testing
- SUBLIVAC® Grasses treatment
- Where
- 60 sites in Belgium, Germany and 2 more
- Volunteers
- 350 people
- Sponsor
- HAL Allergy
Allergic Conjunctivitis
Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis
- Trial name
- NCT00882687
- Testing
- Lifitegrast
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Shire
Allergic Conjunctivitis
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
The purpose of this study is to evaluate the efficacy of loteprednol etabonate ophthalmic base, compared to loteprednol etabonate ophthalmic suspension, and vehicle in the prevention of the signs and symptoms of allergic…
- Trial name
- NCT01107405
- Testing
- Loteprednol etabonate base (QD), Loteprednol etabonate base (BID), Loteprednol etabonate base (QID)
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
A Study of TL-925 for the Treatment of Allergic Conjunctivitis
In this prospective Phase 2, single-center, randomized, double-masked, placebo-controlled study, approximately 70 subjects with allergic conjunctivitis will be randomized 1:1 to receive either TL-925 or placebo as topical…
- Trial name
- NCT06153342
- Testing
- TL-925
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Telios Pharma, Inc.
Allergic Rhinitis, Allergic Conjunctivitis
The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo
The primary objective of this study is to assess the relative efficacy of Ectoin® Allergy Eye Drops and Ectoine® Allergy Nasal Spray compared to placebo, by evaluating Total Nasal Symptom Score (TNSS) and Total Ocular Symptom…
- Trial name
- PPL-003 (NCT01471184)
- Testing
- Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- Bitop AG
Allergic Conjunctivitis
A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy
This study is researching 2 experimental drugs, REGN1908 and REGN1909, which are called REGN1908-1909 when mixed together (called "study drug") to reduce eye allergy signs and symptoms from cat allergy.
- Trial name
- NCT06602726
- Testing
- REGN1908, REGN1909
- Where
- 4 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Regeneron Pharmaceuticals
Allergic Conjunctivitis
Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- AC-170 (NCT01332188)
- Testing
- AC-170 0.05%, AC-170 0.1%, AC-170 0.24%
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aciex Therapeutics, Inc.
Allergic Conjunctivitis, Rhinoconjunctivitis
Ocular Allergy Treatment Practical Impact Trial
To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.
- Trial name
- (OAT-PIT) (NCT01808768)
- Testing
- Alcaftadine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Starx Research Center, LLC
Rhinitis, Allergic, Seasonal
Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)
The purpose of this study is to assess the safety and tolerability of MK-3641 (short ragweed [Ambrosia artemisiifolia] extract, SCH 039641, RAGWITEK®) sublingual tablets and MK-7243 (Timothy grass [Phleum pratense] extract, SCH…
- Trial name
- NCT02256553
- Testing
- MK-3641 12 Amb a 1-U (short ragweed extract), MK-7243 2800 BAU (Timothy grass extract), Rescue Medication
- Volunteers
- 102 people
- Sponsor
- ALK-Abelló A/S